Primary Ciliary Dyskinesia — Research Summary

Printed from RareWays (rareways.com.au) on 5 April 2026

For general awareness only. Not medical advice. Discuss all care options with your healthcare team.

5 Most Recent Research Articles

1.
CircRNA-regulated programmed cell death networks in cardiomyocytes: Molecular crosstalk and therapeutic translation.
Jiang Wenhua et al. — Non-coding RNA research (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41631272/
2.
A systems biology approach to programmed cell death in prostate cancer: Biomarker discovery and therapeutic potential of DL-PDMP.
Oktem Elif Kubat et al. — Computational biology and chemistry (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41576692/
3.
Inertial Cavitation-based Release Estimation - ICbRE.
George Benedikt et al. — Ultrasonics (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41481948/
4.
FOXE1 promotes the progression of pulp inflammation by activating PANoptosis in dental pulp cells.
Gu Fan et al. — iScience (17 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41869565/
5.
Deep Learning-based Monoenergetic Imaging for Calcified Coronary Stenosis Assessment at Energy-integrating Detector CT.
Chang Shaojie et al. — Radiology. Cardiothoracic imaging (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41854396/

Clinical Trials — Currently Recruiting (Australia)

Ask your doctor whether you or your child may be eligible for any of these trials.

1.
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Recruiting — Early Phase 1 — Radiopharm Theranostics, Ltd
https://clinicaltrials.gov/study/NCT06305962
2.
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Recruiting — Phase 1 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT04938817
3.
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Recruiting — Phase 2 — BioNTech SE
https://clinicaltrials.gov/study/NCT04534205
4.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Recruiting — Phase 3 — AstraZeneca
https://clinicaltrials.gov/study/NCT06627647
5.
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Recruiting — Phase 2 — Charite University, Berlin, Germany
https://clinicaltrials.gov/study/NCT03590171
6.
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Recruiting — Phase 2 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06961006
7.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Recruiting — Phase 3 — AstraZeneca
https://clinicaltrials.gov/study/NCT06868277
8.
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Recruiting — Phase 1 — Anbogen Therapeutics, Inc.
https://clinicaltrials.gov/study/NCT07244705
9.
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06966700
10.
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Recruiting — Phase 3 — Pfizer
https://clinicaltrials.gov/study/NCT07144280
11.
THIO Sequenced With Cemiplimab in Advanced NSCLC
Recruiting — Phase 2 — Maia Biotechnology
https://clinicaltrials.gov/study/NCT05208944
12.
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06841354
13.
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Recruiting — Phase 2 — Iovance Biotherapeutics, Inc.
https://clinicaltrials.gov/study/NCT04614103
14.
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Recruiting — Phase 1 — ModernaTX, Inc.
https://clinicaltrials.gov/study/NCT05533697
15.
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Recruiting — Phase 1 — Queensland Institute of Medical Research
https://clinicaltrials.gov/study/NCT06157541
16.
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06345729
17.
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Recruiting — Phase 2 — Melanoma Institute Australia
https://clinicaltrials.gov/study/NCT06288191
18.
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06312176
19.
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06623422
20.
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06170788
21.
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06952504
22.
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Recruiting — Phase 2 — Australia New Zealand Gynaecological Oncology Group
https://clinicaltrials.gov/study/NCT05619913

Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.

Always verify information with your healthcare team before making any decisions about your care.

ICD J98.09ORPHA:244PCD

Primary Ciliary Dyskinesia

Primary ciliary dyskinesia is a rare genetic condition caused by defective cilia function, leading to chronic respiratory infections, bronchiectasis, and fertility problems. Kartagener syndrome (with situs inversus) is a subset. It is significantly underdiagnosed. No disease-modifying therapies currently exist, but several are in trials.

↓ Latest research ↓ Clinical trials(349 recruiting)↓ Research library (542 articles)

542

Articles

1824

Trials (142 AU)

Updated

26 March 2026

Most Recent Research

CircRNA-regulated programmed cell death networks in cardiomyocytes: Molecular crosstalk and therapeutic translation.

Jiang Wenhua et al.Non-coding RNA research1 June 2026

Cardiovascular diseases (CVDs) represent the predominant global health burden, where dysregulated programmed cell death (PCD) mechanisms critically drive myocardial injury pathogenesis. Circular RNAs (circRNAs), characterized by covalently closed structures conferring high stability, function as pivotal regulators coordinating cardiomyocyte fate through integrated networks encompassing ferroptosis, apoptosis, pyroptosis, autophagy, and necroptosis. This review synthesizes advances in understanding circRNA-mediated PCD modulation via molecular sponging, protein interactions, and epigenetic regulation. Key insights establish context-dependent circRNA functionality and validate circRNA-based diagnostic panels for CVDs stratification with enhanced accuracy. Therapeutically, viral vector-delivered protective circRNAs demonstrate significant efficacy in ameliorating post-infarction apoptosis and improving cardiac function. We further evaluate emerging CRISPR-based editing technologies and nanoplatform delivery systems for clinical translation, positioning circRNA networks as promising theranostic targets while highlighting unresolved questions regarding pathway crosstalk and tissue-specific delivery.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.